Study to Evaluate Safety and Efficacy of EG-301 in Patients With Nonfocal Geographic Atrophy Secondary to Dry-AMD

NCT05170048 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Exudative (Dry) Age-related Macular Degeneration (dAMD)

Interventions

DRUG: EG-301
DIETARY_SUPPLEMENT: AREDS2 supplements

Sponsor

Evergreen Therapeutics, Inc.